Stay up to date with all the goings-on in the south of Spain amid a crucial one-day Test ...

CDC's RSV vaccine recommendations from Pfizer and GSK face review by HHS advisor William "Reyn" Archer III. Read more here.

New Zealand has the world's highest rates of serious illness caused by RSV, with 2000 children under five admitted to ...

GlaxoSmithKline Pharmaceuticals Limited has announced that Sukanya Choudhury, Executive Vice President - Regulatory Affairs ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

GSK’s dealmaking will be “cautious and disciplined” under the current trade war, but the pharma will focus on looking for ...

The FTSE 100 drugmaker said it was "well positioned" to tackle the impact of sector-specific tariffs as speculation mounts ...

GSK on Wednesday said it was "well positioned" to absorb potential U.S. pharmaceutical tariffs, citing AI-driven cost cuts ...

GSK posted higher profit as sales for its specialty treatments including HIV, cancer and asthma beat expectations, offsetting lower vaccine sales on weak demand in the U.S.

Higher demand for its specialty medicines business offset a decline of Arexvy sales for respiratory syncytial virus and sales ...

Vulnerable Australians aged 50-59 will be able to receive a vaccine for respiratory syncytial virus (RSV).

We expect GSK's specialty products like Cabenuva, Juluca, Dovato, Nucala, Ojjaara, Jemperli and Trelegy Ellipta to have driven first-quarter sales performance.